Ketamine Infusions

Restoring Hope

Since getting approved for usage by the FDA in March 2019, ketamine has been a glimpse of hope to patients with treatment-resistant MDD due to its rapid efficacy and relatively less adverse effects in comparison to other antidepressant medications. This has provided some relief to the patients, their families and clinicians.